Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing.
The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.
Create products through Biotechnology route and service offerings that enrich the lives of people by continually building on our expertise in Biotechnology.
We strive to be a global power in the field of Biotechnology based products through research and development to create sustainable earnings growth and to establish long term business success. We continue to reinforce our commitment to safety, health and environment. We endeavor for an environment where creativity and effectiveness are encouraged with the technologies for the niche market
Company NewsDec 2010Filed USDMF for Sirolimus. Concord now DMFs for 9 productsOct 2010Successful participation in CPHI, Paris with its first independent booth. Sept 2010Successful launch of Tacrolimus in US market with its ANDA partner. Concord now supplies four products commercially in the US market.Sept 2010Foundation stone laid for state-of-the- art R&D facility. Another plant for low volume & high value products commissioned making the total number of manufacturing blocks as 16.Aug 2010Yet another expansion in the fermentation capacity by 25%. Total fermentation capacity now over 450 m3July 2010Filed J-DMF for TacrolimusRead more...